iBio(NASDAQ) IBIO

Market Cap$69.05M

Since IPO (2008)-100%

5 Year-100%

1 Year+96%

1 Month-17%

$1.36

-2.16%

-0.03Today

iBio last closing stock price
Metric	Price	Date
Last close	USD 1.39	2026-07-28

iBio stock price return by period
Period	Price return	Price at period start	Period start date
1 week	-1.42%	USD 1.41	2026-07-21
1 month	-16.77%	USD 1.67	2026-06-26
3 month	-14.2%	USD 1.62	2026-04-29
Year to date	-27.98%	USD 1.93	2025-12-31
1 year	+95.77%	USD 0.71	2025-07-28
3 year	-86.28%	USD 10.13	2023-07-28
5 year	-99.78%	USD 625.00	2021-07-29
Since inception	-99.97%	USD 4,750.00	2008-08-19

iBio Financials at a Glance

Market Cap

$69.05M

Revenue (TTM)

$300.00K

Net Income (TTM)

-$27.61M

EPS (TTM)

-$0.58

P/E Ratio

-2.41

Dividend

$0.00

Beta (Volatility)

1.34 (Average)

Dividend

$0.00

Beta (Volatility)

1.34 (Average)

Price

$1.36

Volume

802,898

Open

$1.39

Price

$1.36

Volume

802,898

Open

$1.39

Previous Close

$1.36

Daily Range

$1.29 - $1.41

52-Week Range

$0.56 - $3.82

Estimated Earnings Date

Sep 4, 2026

Dividend

$0.00

Beta (Volatility)

1.34 (Average)

Price

$1.36

Volume

802,898

Open

$1.39

Previous Close

$1.36

Daily Range

$1.29 - $1.41

52-Week Range

$0.56 - $3.82

Estimated Earnings Date

Sep 4, 2026

IBIO News

Is It Too Late to Buy iBio Stock?

Zhiyuan SunOct 29, 2020

3 Popular Robinhood Stocks That Could Realistically Double Within 1 Year

Keith SpeightsOct 8, 2020

3 Compelling Biotech Stocks to Consider Buying While They're Hot on Robinhood

Alex CarchidiSep 20, 2020

Page 1

Motley Fool Moneyball Superscore

Our CEO Is Handing Members His Secret Weapon

It's called Motley Fool Moneyball, our new proprietary AI tool

We spent over half a million dollars in R&D to build a tool that makes stock research faster, sharper, and smarter. Our analysts use it every day, and now, you can too.

Get Access Now

About iBio

iBio develops new medicines using artificial intelligence to design antibodies. Its main products aim to treat diseases like obesity and cancer. These solutions help researchers and drug companies find better treatments faster.

Lab Bench to Bedside: What iBio Sells

Therapeutic Antibodies: AI-designed antibodies for obesity, heart disease, and cancer (in preclinical development; not generating product revenue as of February 2026).
Vaccine Candidates: Early-stage vaccines for COVID-19 and animal diseases, targeting researchers and pharmaceutical partners.
Antibody Discovery Platforms: Proprietary tools like StableHu and EngageTx, used by scientists to optimize new drugs.
Licensing and Collaborations: Revenue from partnerships with universities and biotech firms, supporting research and development.

Plot Twists and Pivots: Growth & Expansion

Sold its manufacturing facility in Texas to focus on drug discovery in May 2024.
Signed exclusive licenses with AstralBio in 2024 for obesity and metabolic disease antibodies.
Partnered with Planet Biotechnology and University of Natural Resources and Life Sciences, Vienna for infectious disease research.
Collaborated with The Texas A&M University System for COVID-19 vaccine development.
Transferred stock listing to Nasdaq Capital Market in March 2025.

What Makes iBio Stand Out in a Crowd

iBio uses artificial intelligence to design antibodies that target specific disease proteins. Its technology platforms help speed up drug discovery and improve accuracy. The company focuses on early-stage research, working with partners to share costs and risks.

Five Things You Need to Know

Revenue was $100,000 in QQ1 2026, a 100% increase over QQ1 2024.
Operating loss was $6 million in QQ1 2026, which represents a 44.9% greater loss year-on-year.
Cash and equivalents were $5.2 million as of March 31, 2025.
All revenue comes from collaborations and licensing, not product sales.

Bottom Line

iBio has shifted from manufacturing to AI-driven drug discovery, focusing on antibody research. The company relies on partnerships and licensing to fund its early-stage pipeline.

AI Generated • Apr 16, 2026

Industry

Biotechnology

Sector

Health Care

Employees

CEO

Martin B. Brenner, PhD, DVM

Website

www.ibioinc.com

Headquarters

San Diego, CA 92121, US

IBIO Financials

Key Financial Metrics (TTM)

Gross Margin

-160.00%

Operating Margin

-7985.33%

Net Income Margin

-9202.00%

Return on Equity

-53.86%

Return on Capital

-101.16%

Return on Assets

-32.16%

Earnings Yield

-41.49%

Dividend Yield

0.00%

Payout Ratio

0.00%

Stock Overview

Market Cap

$69.05M

Shares Outstanding

49.68M

Volume

802.90K

Avg. Volume

968.14K

Financials (TTM)

Gross Profit

-$480.00K

Operating Income

-$23.96M

EBITDA

-$26.40M

Operating Cash Flow

-$21.61M

Capital Expenditure

-$560.00K

Free Cash Flow

-$22.17M

Cash & ST Invst.

$74.80M

Total Debt

$2.33M

iBio Performance Analysis

iBio annual revenue and year-over-year revenue growth by fiscal year
Fiscal year	Period end	Revenue	YoY growth
2022	2022-06-30	USD 1,884,000	N/A
2023	2023-06-30	USD 0	N/A
2024	2024-06-30	USD 225,000	N/A
2025	2025-06-30	USD 400,000	77.8%

iBio sequential (quarter-over-quarter) revenue growth by fiscal quarter
Fiscal quarter	Period end	QoQ growth
Q4	2025-06-30	N/A
Q1	2025-09-30	-50.0%
Q2	2025-12-31	-100.0%
Q3	2026-03-31	N/A

iBio annual diluted earnings per share and year-over-year EPS growth by fiscal year
Fiscal year	Period end	Diluted EPS	YoY growth
2022	2022-06-30	USD -2,889.06	N/A
2023	2023-06-30	USD -106.18	-96.3%
2024	2024-06-30	USD -6.50	-93.9%
2025	2025-06-30	USD -1.75	-73.1%

iBio sequential (quarter-over-quarter) diluted earnings per share growth by fiscal quarter
Fiscal quarter	Period end	QoQ growth
Q4	2025-06-30	36.7%
Q1	2025-09-30	64.5%
Q2	2025-12-31	17.5%
Q3	2026-03-31	28.8%

Revenue Growth Rate

Annual and quarterly growth comparison

Earnings Per Share Growth Rate

Annual and quarterly EPS growth comparison

Quarterly Performance

Name

Q3 2026YOY CHG

Revenue

$0.00

N/A

Gross Profit

-$250.00K

N/A

Gross Margin

0.00%

N/A

Market Cap

$69.05M

N/A

Market Cap/Employee

$3.45M

N/A

Employees

N/A

Net Income

-$7.73M

-59.0%

EBITDA

-$7.46M

-64.8%

Quarterly Fundamentals

Name

Q3 2026YOY CHG

Total Cash

$74.80M

+1408.3%

Total Debt

$2.33M

-38.1%

Accounts Receivable

$0.00

N/A

Inventory

$0.00

N/A

Long Term Debt

$1.79M

-22.9%

Short Term Debt

$532.00K

-62.8%

Return on Assets

-32.16%

N/A

Return on Invested Capital

-30.20%

N/A

Free Cash Flow

-$6.10M

-95.4%

Operating Cash Flow

-$6.08M

-95.9%

Other Investments to Explore

People Also Watch

SymbolSymbol / CompanyCompanyPricePrice Chg

BOLDBoundless Bio, Inc.

BOLDBoundless Bio, Inc.$2.48+0.40%

RLYBRallybio Corporation

RLYBRallybio Corporation$15.96-1.21%

KLTOKlotho Neurosciences, Inc.

KLTOKlotho Neurosciences, Inc.$0.38-7.10%

PLURPluri Inc.

PLURPluri Inc.$1.58-8.14%

INTSIntensity Therapeutics, Inc.

INTSIntensity Therapeutics, Inc.$4.33-3.78%

XCURExicure, Inc.

XCURExicure, Inc.$1.73-0.57%

PSTVPlus Therapeutics, Inc.

PSTVPlus Therapeutics, Inc.$3.63-3.46%

Trending Stocks

SymbolSymbol / CompanyCompanyPricePrice Chg

SOFISoFi Technologies

SOFISoFi Technologies$15.25-0.09%

INTCIntel

INTCIntel$81.88-0.05%

NVDANvidia

NVDANvidia$190.01-0.04%

TQQQProShares Trust - ProShares UltraPro Qqq

TQQQProShares Trust - ProShares UltraPro Qqq$57.75-0.06%

FFord Motor Company

FFord Motor Company$15.28+0.02%

NOKNokia

NOKNokia$8.41-0.06%

JBLUJetBlue Airways

JBLUJetBlue Airways$5.72-0.05%

Questions About IBIO

What is the current price of iBio?

iBio is trading at $1.36 per share.

What is the 52-week range for iBio?

Over the past 52 weeks, iBio has traded between $0.56 and $3.82.

How much debt does iBio have?

As of the most recent reporting period, iBio reported total debt of $2.33M.

How much cash does iBio have on hand?

iBio reported $47.63M in cash and cash equivalents in its most recent financial results.

What is iBio’s dividend yield?

iBio does not currently have a dividend yield.

iBio(NASDAQ) IBIO

iBio Financials at a Glance

IBIO News

This Under-the-Radar Pharma Company Could Be a Bargain Hunter's Dream

Here's Why iBio Stock Surged Friday

Why iBio Stock Soared Today

Why iBio Stock Soared Today

These 4 Micro-Cap Healthcare Stocks Gained the Most in 2020

Is It Too Late to Buy iBio Stock?

3 Popular Robinhood Stocks That Could Realistically Double Within 1 Year

3 Compelling Biotech Stocks to Consider Buying While They're Hot on Robinhood

Motley Fool Moneyball Superscore

Our CEO Is Handing Members His Secret Weapon

About iBio

Lab Bench to Bedside: What iBio Sells

Plot Twists and Pivots: Growth & Expansion

What Makes iBio Stand Out in a Crowd

Five Things You Need to Know

Bottom Line

IBIO Financials

Key Financial Metrics (TTM)

Stock Overview

Financials (TTM)

iBio Performance Analysis

Revenue Growth Rate

Earnings Per Share Growth Rate

Quarterly Performance

Quarterly Fundamentals

Other Investments to Explore

People Also Watch

Trending Stocks

Questions About IBIO

What is the current price of iBio?

What is the 52-week range for iBio?

How much debt does iBio have?

How much cash does iBio have on hand?

What is iBio’s dividend yield?

Premium Investing Services